keynote-412: pembrolizumab with crt vs placebo plus crt for locally advanced hnscc
Published 1 year ago • 133 plays • Length 2:57Download video MP4
Download video MP3
Similar videos
-
2:17
#esmo22 highlights on pembrolizumab with crt in locally advanced hnscc: the keynote-412 study
-
9:06
study shows trend toward improved efs for pembrolizumab crt versus placebo crt for locally a...
-
1:11
keynote-412 trial
-
5:45
pembro crt in hnscc fails to deliver statistically significant event-free survival improvement
-
8:28
outcomes for patients with locally advanced head and neck cancer receiving neoadjuvant pembrolizumab
-
1:41
phase ii trial of pembrolizumab and cabozantinib in hnscc
-
2:21
final analysis of keynote-585: pembrolizumab and chemotherapy in g/gej cancer
-
2:26
sd-101 plus pembrolizumab for hnscc
-
1:00:19
april 2023 case conference webinar
-
3:04
head and neck cancer at asco 2022
-
1:18:31
current oncology update series : 9
-
1:59
pembrolizumab in the treatment of head and neck cancer: is there more to the story?
-
2:09
keynote-240: pembrolizumab in advanced hcc
-
2:25
keynote-224: second-line pembrolizumab for advanced hepatocellular carcinoma
-
1:36
addition of an egfr/tgfβ inhibitor with pembrolizumab in head and neck cancer
-
1:41
cancer procedure: ct guided injection of immunotherapy into squamous cell carcinoma of head and neck
-
7:53
pembrolizumab for persistent, recurrent, or metastatic cervical cancer
-
0:53
clinical trials evaluating immune checkpoint blockade and radiotherapy in head and neck cancer
-
0:40
dr. vokes on selecting nivolumab or pembrolizumab for head and neck cancer treatment
-
6:36
pembrolizumab in advanced squamous cell carcinoma of the head and neck
-
1:21
keynote-921: pembrolizumab plus docetaxel in chemotherapy-naïve mcrpc